Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells $155,817.69 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 15,787 shares of the firm’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $155,817.69. Following the completion of the sale, the insider now directly owns 492,832 shares in the company, valued at approximately $4,864,251.84. The trade was a 3.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Moatazedi also recently made the following trade(s):

• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40.

Evolus Trading Down 3.0%

EOLS stock opened at $9.70 on Friday. The company has a market capitalization of $625.42 million, a PE ratio of -10.66 and a beta of 1.11. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82. The company’s 50 day moving average price is $11.32 and its two-hundred day moving average price is $12.33.

Hedge Funds Weigh In On Evolus

Several institutional investors and hedge funds have recently made changes to their positions in EOLS. Principal Financial Group Inc. boosted its position in Evolus by 9.8% during the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock valued at $368,000 after buying an additional 2,989 shares during the period. Barclays PLC lifted its stake in shares of Evolus by 12.9% in the 4th quarter. Barclays PLC now owns 105,786 shares of the company’s stock valued at $1,167,000 after acquiring an additional 12,124 shares during the last quarter. Frontier Capital Management Co. LLC purchased a new stake in Evolus during the 4th quarter valued at about $2,648,000. Raymond James Financial Inc. bought a new position in Evolus during the 4th quarter worth approximately $575,000. Finally, JPMorgan Chase & Co. increased its stake in Evolus by 63.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock worth $2,753,000 after purchasing an additional 65,972 shares during the period. Institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on EOLS. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. BTIG Research assumed coverage on shares of Evolus in a research report on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price for the company. Barclays increased their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus has a consensus rating of “Buy” and an average target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.